PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Revenue decline while TRAW shows 1.79% growth. Joel Greenblatt would examine competitive position erosion.
31.39%
Similar cost growth to TRAW's 33.33%. Walter Schloss would investigate if industry cost pressures are temporary.
-116.81%
Gross profit decline while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive position.
-451.18%
Both companies show margin pressure. Martin Whitman would check industry conditions.
6.71%
R&D growth above 1.5x TRAW's 1.75%. Michael Burry would check for spending discipline.
86.34%
G&A change of 86.34% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
29.34%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
31.39%
Similar D&A growth to TRAW's 33.33%. Walter Schloss would investigate industry patterns.
-52.58%
EBITDA decline while TRAW shows 0.31% growth. Joel Greenblatt would examine position.
-3087.14%
EBITDA margin decline while TRAW shows 2.06% growth. Joel Greenblatt would examine position.
-52.01%
Operating income decline while TRAW shows 0.29% growth. Joel Greenblatt would examine position.
-3075.40%
Operating margin decline while TRAW shows 2.04% growth. Joel Greenblatt would examine position.
137.14%
Other expenses growth less than half of TRAW's 860.00%. David Dodd would verify if advantage is sustainable.
-51.43%
Pre-tax income decline while TRAW shows 2.38% growth. Joel Greenblatt would examine position.
-3063.27%
Pre-tax margin decline while TRAW shows 4.09% growth. Joel Greenblatt would examine position.
100.00%
Tax expense growth above 1.5x TRAW's 0.00%. Michael Burry would check for concerning trends.
-52.47%
Net income decline while TRAW shows 2.38% growth. Joel Greenblatt would examine position.
-3085.00%
Net margin decline while TRAW shows 4.09% growth. Joel Greenblatt would examine position.
-43.48%
EPS decline while TRAW shows 5.00% growth. Joel Greenblatt would examine position.
-43.48%
Diluted EPS decline while TRAW shows 5.00% growth. Joel Greenblatt would examine position.
7.17%
Share count change of 7.17% while TRAW is stable. Bruce Berkowitz would verify approach.
7.17%
Diluted share change of 7.17% while TRAW is stable. Bruce Berkowitz would verify approach.